Service notifications for recommended Technology Appraisals (TAs)
Technology Appraisals are listed below in alphanumerical order with links to further information on the NICE website.
| Title | Description | Date added | Download |
|---|---|---|---|
| NICE TA1120 (review of TA645) | Service Notification Avelumab with axitinib for untreated advanced renal cell carcinoma | 29-04-2026 | DownloadPreview |
| NICE TA1131 | Service Notification Obinutuzumab with mycophenolate mofetil for treating lupus nephritis | 29-04-2026 | DownloadPreview |
| NICE TA1134 (review of TA648) | Service Notification Dupilumab for treating severe chronic rhinosinusitis with nasal polyps | 29-04-2026 | DownloadPreview |
| NICE TA878 | UPDATE Nirmatrelvir plus ritonavir and tocilizumab for treating COVID-19 | 29-04-2026 | DownloadPreview |
| NICE TA1056 | Service Notification Molnupiravir for treating COVID-19 (update) | 29-04-2026 | DownloadPreview |
| NICE TA1122 | Service Notification Amivantamab with lazertinib for untreated EGFR mutation-positive advanced non-small-cell lung c | 29-04-2026 | DownloadPreview |
| NICE TA1119 (review of TA663) | Service Notification Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia | 29-04-2026 | DownloadPreview |
| TA1121 | Service Notification Acoramidis for treating transthyretin amyloidosis with cardiomyopathy | 20-03-2026 | DownloadPreview |
| TA1107 | Service Notification Delgocitinib for treating moderate to severe chronic hand eczema | 09-03-2026 | DownloadPreview |
| TA1106 | Service Notification Cabotegravir for preventing HIV-1 in adults and young people | 04-03-2026 | DownloadPreview |
| TA1117 | Dostarlimab with platinum-containing chemotherapy for treating primary advanced or recurrent endometrial cancer with microsatellite stability or mismatch repair proficiency | 04-03-2026 | DownloadPreview |
| TA1116 | Service Notification Obecabtagene autoleucel for treating relapsed or refractory B-cell precursor acute lymphoblasti | 24-02-2026 | DownloadPreview |
| TA1115 | Vutrisiran for treating transthyretin amyloidosis with cardiomyopathy | 23-02-2026 | DownloadPreview |
| TA1114 | Talquetamab for treating relapsed and refractory multiple myeloma after 3 or more treatments | 20-02-2026 | DownloadPreview |
| TA1113 | Glofitamab with gemcitabine and oxaliplatin for treating relapsed or refractory diffuse large B-cell lymphoma | 19-02-2026 | DownloadPreview |
| TA1110 | Abiraterone (originator and generics) for treating newly diagnosed high-risk hormone‑sensitive metastatic prostate cancer (review of TA721) | 19-02-2026 | DownloadPreview |
| TA1066 | Service Notification Somapacitan for treating hormone deficiency in people 3 to 17 years | 19-02-2026 | DownloadPreview |
| TA1087 | Service Notification Betula verrucose for treating moderate to severe allergic rhinitis or conjunctivitis caused by tree pollen | 19-02-2026 | DownloadPreview |
| TA1109 | Service Notification Darolutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer | 17-02-2026 | DownloadPreview |
| TA1103 (review of TA909) | Service Notification Lorlatinib for ALK-positive advanced non-small-cell lung cancer that has not been treated with an ALK inhibitor (review of TA909) | 13-02-2026 | DownloadPreview |